MSA Announces Record Fourth Quarter and Full ... ( Established in 1914 MSA is a global ...)

MSA Announces Record Fourth Quarter and Full Year Sales

Date:2/26/2009

Established in 1914, MSA is a global leader in the development, manufacture and supply of sophisticated safety products that protect people's health and safety. Sophisticated safety products typically integrate any combination of electronics, mechanical systems and advanced materials to protect users against hazardous or life-threatening situations. The company's comprehensive line of products is used by workers around the world in the fire service, homeland security, construction and other industries, as well as the military. Principal products include self-contained breathing apparatus, gas masks, gas detection instruments, head protection, respirators and thermal imaging cameras. The company also provides a broad range of consumer and contractor safety products through retail channels. These products are marketed and sold under the MSA Safety Works brand. MSA has annual sales of approximately $1 billion, manufacturing operations throughout the United States and Europe, and 42 international locations. Additional information is available on the company's Web site at www.msanet.com.

Cautionary Statement Regarding Forward-Looking Statements:

Except for historical information, certain matters discussed in this press release may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including without limitation all projections and anticipated levels of future performance, involve risks, uncertainties and other factors that may cause our actual results to differ materially from those discussed herein. Actual results can be affected by any number of factors, many of which are outside of management's control. Among the factors that could cause such differences are global economic conditions, s
'/>"/>

SOURCE MSA
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories

Post Your Comments:

(Date:12/16/2009)... (Nasdaq: BLUD ), a global leader in providing ... announced that Paul D. Mintz, M.D. has been appointed ... January 1, 2010. ,, Dr. Mintz has been ... than 30 years. He is a tenured Professor of ... of Medicine. He also serves as director of the ...

(Date:12/16/2009)... of C3: Colorectal Cancer Coalition,s advocacy efforts, $15 million ... included in the final Fiscal Year 2010 Defense Appropriations ... research cancers, like colorectal cancer, that are not addressed ... programs run by the U.S. Army Medical Research and ... funding for this new cancer research program was included ...

(Date:12/16/2009)... led by the Wellcome Trust Sanger Institute announce the ... cancers are caused by mutations in the DNA of ... The studies, of a malignant melanoma and a lung ... mutations in the genomes of two cancers. , Lung ... almost all are associated with smoking. The number of ...

(Date:12/16/2009)... to Quality, Cost-Effective Care , ... Washington, D.C. (Vocus) ... the best ways to rein in runaway costs while providing care ... part of the ongoing discussion includes how to ensure patients equal ... of medicine (MDs) or osteopathy (DOs). In both the House ...

(Date:12/16/2009)... MassBio promote Massachusetts companies through annual marketing campaign , ... ... -- BioSpace unveiled the 2010 Genetown™ Hotbed Campaign ... , , ,Genetown is sponsored by MassBio and ... industries. The campaign places each entity’s brand on an ...

Breaking Medicine News(10 mins):Health News:Immucor Appoints New Board Director 2 Health News:House Creates New Cancer Research Program 2 Health News:House Creates New Cancer Research Program 3 Health News:Lung cancer and melanoma laid bare 2 Health News:Lung cancer and melanoma laid bare 3 Health News:Lung cancer and melanoma laid bare 4 Health News:Lung cancer and melanoma laid bare 5 Health News:Lung cancer and melanoma laid bare 6 Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 2 Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 3 Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 4 Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 5 Health News:Thriving Bioscience Region Leaves Its Mark 2

[1] Immucor Appoints New Board Director [0] House Creates New Cancer Research Program [1] Lung cancer and melanoma laid bare [1] Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs [0] Thriving Bioscience Region Leaves Its Mark

... neurological disorder in which misfiring electrical impulses in the ... epilepsy, and more than a million are female. //Pregnant ... that their children will have problems ranging from congenital ... to growing evidence that many commonly prescribed anti-epileptic drugs ...

... treatments may further increase the risk of breast and ... //Researchers offer new evidence that herbs such as red ... - as well as saw palmetto and rhodiola rosea ... could increase the risk of estrogen-related cancers. ...

... for long hours are more likely to be agitated.The ... and the New York State Psychiatric Institute. His team tracked ... found that those who had watched one or more hours ... into fights or behave aggressively towards other people later in ...

... According to a study, siblings of people with Alzheimer's ... of dementia.// More than half of patients with Alzheimer's ... This is an especially serious form of the condition, ... earlier need for institutional care. ,Researchers at ...

... Researchers say they've taken a major step toward cloning ... transplanted into humans. Such organs would save the lives ... transplants because of the shortage of human organs.// ... Dolly, scientists say they produced four piglets without one ...

... anxiety during pregnancy can increase a mother's risk of ... who were very anxious// in the last three months ... ,Lead researcher Professor Vivette Glover, of Imperial College, ... had extreme anxiety, and were frequently feeling scared.According ...

Other Medicine News:Health News: Pig cloning for organs, 2

Epilepsy Drugs Can Enhance Risk of Birth Defects Herbs With Estrogen Action Aggravate Cancer Risk Watching television for long hours could lead to agressiveness,Alzheimer's with psychosis runs in families Pig cloning for organs,Anxiety likely to affect the foetus

(Date:12/16/2009)... -- Cohera Medical Inc. today announced the treatment ... its lead surgical adhesive product, TissuGlu®. Initiation of ... company,s progression of the lead product toward clinical ... prospective, open-label, randomized study to investigate the safety ... and associated complications in abdominoplasty, or "tummy tuck," ...

(Date:12/16/2009)... Dec. 16 CareCentrix, Inc ., ... management services, announced today that it has been ... DC-based health care accrediting organization that establishes quality ... guarantee that only appropriately trained, qualified clinical personnel ... a reasonable and timely appeals process is in ...

(Date:12/16/2009)... CHARLOTTESVILLE, Virginia, December 16 Biovista Inc.,today ... Innovator Presentation Award,in Healthcare, at the 2009 New ... MA. The award, which recognizes cutting edge private ... Biovista who competed with,over 50 other privately held ... the Technology, Life Sciences and Clean-tech sectors. , ...

Breaking Medicine Technology:First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 2 First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 3 CareCentrix Receives URAC Health Utilization Management Accreditation 2 Biovista Inc. Named Top Innovator in Life Sciences 2 MapleWorks 26apos 3B Video Application Development Technology Allows for High Level of Collaboration Cooperation 58626 1 MapleWorks 26apos 3B Video Application Development Technology Allows for High Level of Collaboration Cooperation 58626 2 MapleWorks 26apos 3B Video Application Development Technology Allows for High Level of Collaboration Cooperation 58626 3 Oakstone Medical Publishing Launches Unique Website Specifically Geared to Radiologists and Their Continuing Education Needs 58624 1 Oakstone Medical Publishing Launches Unique Website Specifically Geared to Radiologists and Their Continuing Education Needs 58624 2 ZyDoc Solves Medical Data Transfer Issues with ZyDoc Messenger and Managed File Transfer 28MFT 29 Workflow Software 58622 1 ZyDoc Solves Medical Data Transfer Issues with ZyDoc Messenger and Managed File Transfer 28MFT 29 Workflow Software 58622 2 ZyDoc Solves Medical Data Transfer Issues with ZyDoc Messenger and Managed File Transfer 28MFT 29 Workflow Software 58622 3 ZyDoc Solves Medical Data Transfer Issues with ZyDoc Messenger and Managed File Transfer 28MFT 29 Workflow Software 58622 4

[0] First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive [0] CareCentrix Receives URAC Health Utilization Management Accreditation [0] Biovista Inc. Named Top Innovator in Life Sciences

... from three studies,evaluating associations between lower mean baseline ... as well as the possible effect of,restrictions on ... the nation,s blood supply, will be presented at ... later this,month. The meeting will take place in ...

... Results demonstrating that TYKERB and trastuzumab together resulted,in ... -- Combining TYKERB and trastuzumab to attack ... may create a more complete HER2 blockade, ... patients,previous treatment with multiple lines of trastuzumab and ...

Other Medicine Technology:New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2 New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3 New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4 New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5 New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6 GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2 GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3 GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4 GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5 GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6 GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7

New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)

... knee prosthesis stems from many years of ... manufacturing technologies have been used in order ... as a favorable pressure distribution pattern on ... to a minimum. The inherent design of ...

... Knee design includes several innovative ... porous coating option for stable ... unique bone preserving posterior stabilizing ... to maximize range of motion, ...

Advance Posterior Stabilized Total Knee systems improves patellofemoral kinematics, reduces wear rate potential, increases resistance to posterior tibial dislocation, achieves at least 120o flexion i...

Scorpio CR Knee is designed to address normal knee kinematics, range of motion (ROM) and polyethylene wear....

Medicine Products:

RT-PLUS Solution Natural-Knee Advance Posterior Stabilized Total Knee Systems Scorpio CR Knee, cruciate retaining single axis

MSA Announces Record Fourth Quarter and Full ...( Established in 1914 MSA is a global ...),Health